ImmuCell Q2 Sales Jump 12% to $7.2M, Six-Month Revenue Up 21%
ICCC has more than doubled off its 52-week low of $4.52.
Summary
ImmuCell posted preliminary Q2 2026 product sales of $7.2 million, an 11.5% increase year-over-year, driven by a 27.7% surge in domestic sales. International sales fell 38.9% to $1.0 million, but management sees strong end-customer demand in Canada. For the first half, total sales reached $17.5 million, up 20.9%. The growth is notable given a tough comparison against Q2 2025 when distributors restocked after backorders. This follows a strong Q1 reported in May and a $3.5 million capacity expansion approved in June. Full financial results and management commentary are set for the August 14 conference call.
At the time of this announcement, ICCC was trading at $11.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $103.6M. The 52-week trading range was $4.52 to $11.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.